IPHYF
Innate Pharma SA
$1.65
0.00%
No data for this timeframe.
Vol
SEC Reports10
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. I0·CIK 0001598599·Prev Close $1.65
Recent Activity
May 19, 2026
SEC
Innate Pharma announced its executive team will participate in one-on-one investor meetings at the Jefferies Global Heal
6-K — Impact 2/10
May 13, 2026
SEC
Innate Pharma reported Q1 2026 revenue of €2.6M (up from €1.2M YoY) but disclosed a cash position of only €25.4M, provid
6-K — Impact 8/10
May 6, 2026
SEC
Innate Pharma filed a 6-K announcing a Q1 2026 business update conference call scheduled for May 13, 2026. The filing co
6-K — Impact 2/10
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Latest Reports
NEUTRAL
6-K
2/10
Innate Pharma announced its executive team will participate in one-on-one investor meetings at the Jefferies Global Heal
May 19, 2026
BEARISH
6-K
8/10
Innate Pharma reported Q1 2026 revenue of €2.6M (up from €1.2M YoY) but disclosed a cash position of only €25.4M, provid
May 13, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
10 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 7 neutral. Avg impact: 4.1/10.
NEUTRAL
6-K
2/10
Innate Pharma announced its executive team will participate in one-on-one investor meetings at the J
May 19, 2026
BEARISH
6-K
8/10
Innate Pharma reported Q1 2026 revenue of €2.6M (up from €1.2M YoY) but disclosed a cash position of
May 13, 2026
NEUTRAL
6-K
2/10
Innate Pharma filed a 6-K announcing a Q1 2026 business update conference call scheduled for May 13,
May 6, 2026
NEUTRAL
6-K
2/10
Innate Pharma announced executive participation in the D. Boral Capital Global Conference on May 7,
Apr 23, 2026
BULLISH
6-K
7/10
Innate Pharma announced interim Phase 2 results from its MATISSE trial showing a 35.7% pathological
Apr 17, 2026
NEUTRAL
6-K
2/10
Innate Pharma filed a 6-K disclosing its total number of shares outstanding and voting rights as of
Apr 13, 2026
NEUTRAL
6-K
3/10
Innate Pharma announced the date and logistics for its 2026 Annual General Meeting of shareholders,
Apr 13, 2026
NEUTRAL
6-K
4/10
Innate Pharma announced it will present at the AACR 2026 Oncology Industry Partnering Event, highlig
Apr 8, 2026
NEUTRAL
6-K
3/10
Innate Pharma announced that its executive team will participate in one-on-one investor meetings at
Apr 3, 2026
BEARISH
20-F
8/10
Innate Pharma's 20-F filing confirms a cash runway into Q3 2026 but highlights a critical funding ga
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 246.6% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 107.4% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 29, 2026
Clinical Trial
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Phase Phase 2 — COMPLETED